Proinsulin ELISA

Kit Calculator

Estimate required kits based on your number of samples.

Samples

Article no.

Sample setup

Add the number of samples you plan to run. Please ensure that each sample has sufficient volume to meet the kit’s per-well requirement.

Controls

Add a corresponding Mercodia control kit. Note: If controls are selected, more than one control kit may be needed depending on the number of assay kits used and the time between runs

The results show the estimated number of assay kits required based on your input and the assay’s DfU. Actual kit usage may vary depending on workflow and run frequency.

Minimal Number of Kits Required:

(10-1118-03)

RUO

Kit format: 1 x 96 wells

Measurement range: 3.3 - 130 pmol/L (0.03 - 1.18 µg/L)

Measures total proinsulin

Highly specific with no cross-reactivity to human insulin or C-peptide

Calibrated against International Reference Reagent IRR 84/611 for human proinsulin

Serum control available: Diabetes Antigen Control (10-1164-03)

Research Use Only (RUO)

Description

The Proinsulin ELISA is a method for the quantitative determination of human proinsulin in serum or plasma.

The Mercodia Proinsulin ELISA is a highly specific tool calibrated against International Reference Reagent IRR 84/611 for human proinsulin. The specificity of the utilized antibodies enables measurement of human proinsulin without interference from insulin or C-peptide.

Each Mercodia Proinsulin ELISA kit contains reagents for 96 wells, sufficient for 42 samples and one calibrator curve in duplicate. The microplate strip format (12 strips x 8 wells) is ideal when only a limited number of samples need to be analyzed.

Mercodia Diabetes Antigen Control (10-1164-03) is designed to be used as a two-level control for human proinsulin.

Test characteristics

Species

Human

Samples

Serum and plasma

Sample volume

50 µL

Assay range

3.3 - 130 pmol/L (0.03 - 1.18 µg/L)

Detection limit

≤1.7 pmol/L

Incubation

1 h + 1 h + 15 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Insulin

< 0.03 %

C-peptide

< 0.006 %

Proinsulin (Des 31-32)

95 %

Proinsulin (Split 32-33)

95 %

Proinsulin (Des 64-65)

84 %

Proinsulin (Split 65-66)

90 %

Porcine Proinsulin

4 %

Mouse Proinsulin I

3 %

Mouse Proinsulin II

16 %

Rat Proinsulin I

13 %

Rat Proinsulin II

10 %

directions for use Certificate of Analysis

directions for use

LOT. NO.	DOCUMENT
37694	DfU - 10-1118-03 v 1.0

Certificate of Analysis

LOT. NO.	DOCUMENT
37694	CoA - 10-1118-03

For other languages and previous versions: Technical Library

SAFETY DATA SHEET

references

Fraser, A. et al. (2012) Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation 125, 1367–1380. Read more >

AlEssa, H. B. et al. (2017) Dietary patterns and cardiometabolic and endocrine plasma biomarkers in US women. Am. J. Clin. Nutr. 105, 432–441. Read more >

Velazco-Cruz, L. et al. (2019) Acquisition of Dynamic Function in Human Stem Cell Derived β Cells. Stem Cell Reports 12, 351–365. Read more >

Ghiasi, S. M. et al. (2019) Endoplasmic reticulum chaperone glucose-regulated protein 94 is essential for proinsulin handling. Diabetes 68, 747–760. Read more >